Arbor Biotechnologies
CAMBRIDGE, MA · Founded 2016 · CIK 0001707499 · Biotech · Private
Programmable DNA editors for genetic medicine
arbor.bio →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $227M
- 2 Form D · Nov 2021
- 59 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $12,224,999 | |
| Private capital raised | Form D · SEC | $214,999,926 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2787 | Veradermics | — | $269M |
| 2788 | Avalyn Pharma | — | $242M |
| 2789 | Zylo Therapeutics Inc. | — | $4.9M |
| 2790 | Arbor Biotechnologies | — | $227M |
| 2791 | Metsera | — | $215M |
| 2792 | Affinivax, Inc. | — | $233M |
| 2793 | Forge Biologics Holdings, LLC | — | $160M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- MARK ANGELINODirector
- DAVID CHENGExecutive Officer
- KEITH CRANDELLDirector
- RAMI HARAWIDirector
- ANNIE HAZLEHURSTDirector
- PAUL MEISTERDirector
- KELLY MORGANExecutive Officer
- JOHN MURPHYExecutive Officer
- DAVID SCOTTExecutive Officer
- DEVYN SMITHDirector · Executive Officer
- PAM STETKIEWICZExecutive Officer
- DAVID WALTDirector
- WINSTON YANExecutive Officer
- CHEN YUDirector
- FENG ZHANGDirector
Patents
- Novel Crispr Dna Targeting Enzymes And Systemsapplication
- Novel Crispr-associated Systems And Componentsgranted
- Novel Crispr Dna Targeting Enzymes And Systemsgranted
- Novel Crispr Dna Targeting Enzymes And Systemsgranted
- Novel Crispr Dna Targeting Enzymes And Systemsgranted
- Novel Crispr-associated Systems And Componentsgranted
- Novel Crispr Dna Targeting Enzymes And Systemsgranted
- Novel Crispr Rna Targeting Enzymes And Systems And Uses Thereofgranted
- Compositions Comprising A Crispr Nuclease And Uses Thereofapplication
- Crispr-associated Transposon Systems And Methods Of Using Sameapplication
- Compositions Comprising A Crispr Nuclease And Uses Thereofgranted
- Novel Crispr Dna And Rna Targeting Enzymes And Systemsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.